OptimizeRx (OPRX) EBIAT (2016 - 2025)
OptimizeRx (OPRX) has disclosed EBIAT for 16 consecutive years, with $5.0 million as the latest value for Q4 2025.
- Quarterly EBIAT rose 6535.9% to $5.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $5.1 million through Dec 2025, up 125.52% year-over-year, with the annual reading at $5.1 million for FY2025, 125.52% up from the prior year.
- EBIAT hit $5.0 million in Q4 2025 for OptimizeRx, up from $779000.0 in the prior quarter.
- In the past five years, EBIAT ranged from a high of $5.0 million in Q4 2025 to a low of -$9.1 million in Q3 2024.
- Historically, EBIAT has averaged -$2.2 million across 5 years, with a median of -$2.5 million in 2023.
- Biggest five-year swings in EBIAT: plummeted 8790.01% in 2022 and later skyrocketed 6535.9% in 2025.
- Year by year, EBIAT stood at $623462.0 in 2021, then plummeted by 152.26% to -$325836.0 in 2022, then tumbled by 1171.19% to -$4.1 million in 2023, then soared by 98.12% to -$78000.0 in 2024, then surged by 6535.9% to $5.0 million in 2025.
- Business Quant data shows EBIAT for OPRX at $5.0 million in Q4 2025, $779000.0 in Q3 2025, and $1.5 million in Q2 2025.